Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Operating Expenses: 2018-2024

Historic Operating Expenses for Silence Therapeutics (SLN) over the last 7 years, with Dec 2024 value amounting to -$18.9 million.

  • Silence Therapeutics' Operating Expenses fell 5.45% to $26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.5 million, marking a year-over-year decrease of 64.87%. This contributed to the annual value of -$18.9 million for FY2024, which is 69.70% down from last year.
  • As of FY2024, Silence Therapeutics' Operating Expenses stood at -$18.9 million, which was down 69.70% from -$11.1 million recorded in FY2023.
  • In the past 5 years, Silence Therapeutics' Operating Expenses registered a high of $69.9 million during FY2021, and its lowest value of -$18.9 million during FY2024.
  • Moreover, its 3-year median value for Operating Expenses was -$11.4 million (2022), whereas its average is -$13.8 million.
  • In the last 5 years, Silence Therapeutics' Operating Expenses surged by 157.86% in 2020 and then slumped by 116.31% in 2022.
  • Yearly analysis of 5 years shows Silence Therapeutics' Operating Expenses stood at $43.9 million in 2020, then surged by 59.10% to $69.9 million in 2021, then plummeted by 116.31% to -$11.4 million in 2022, then increased by 2.48% to -$11.1 million in 2023, then slumped by 69.70% to -$18.9 million in 2024.